Cargando…
Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
Glioblastoma (GBM) represents the most frequent primary brain tumor in adults and carries a dismal prognosis despite aggressive, multimodal treatment regimens involving maximal resection, radiochemotherapy, and maintenance chemotherapy. Histologically, GBMs are characterized by a high degree of VEGF...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823037/ https://www.ncbi.nlm.nih.gov/pubmed/26575171 http://dx.doi.org/10.18632/oncotarget.6320 |
_version_ | 1782425843875708928 |
---|---|
author | Niyazi, Maximilian Harter, Patrick N. Hattingen, Elke Rottler, Maya von Baumgarten, Louisa Proescholdt, Martin Belka, Claus Lauber, Kirsten Mittelbronn, Michel |
author_facet | Niyazi, Maximilian Harter, Patrick N. Hattingen, Elke Rottler, Maya von Baumgarten, Louisa Proescholdt, Martin Belka, Claus Lauber, Kirsten Mittelbronn, Michel |
author_sort | Niyazi, Maximilian |
collection | PubMed |
description | Glioblastoma (GBM) represents the most frequent primary brain tumor in adults and carries a dismal prognosis despite aggressive, multimodal treatment regimens involving maximal resection, radiochemotherapy, and maintenance chemotherapy. Histologically, GBMs are characterized by a high degree of VEGF-mediated vascular proliferation. In consequence, new targeted anti-angiogenic therapies, such as the monoclonal anti-VEGF-A antibody bevacizumab, have proven effective in attenuating tumor (neo)angiogenesis and were shown to possess therapeutic activity in several phase II trials. However, the role of bevacizumab in the context of multimodal therapy approaches appears to be rather complex. This review will give insights into current concepts, limitations, and controversies regarding the molecular mechanisms and the clinical benefits of bevacizumab treatment in combination with radio(chemo)therapy - particularly in face of the results of recent phase III trials, which failed to demonstrate convincing improvements in overall survival (OS). |
format | Online Article Text |
id | pubmed-4823037 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-48230372016-05-03 Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance? Niyazi, Maximilian Harter, Patrick N. Hattingen, Elke Rottler, Maya von Baumgarten, Louisa Proescholdt, Martin Belka, Claus Lauber, Kirsten Mittelbronn, Michel Oncotarget Review Glioblastoma (GBM) represents the most frequent primary brain tumor in adults and carries a dismal prognosis despite aggressive, multimodal treatment regimens involving maximal resection, radiochemotherapy, and maintenance chemotherapy. Histologically, GBMs are characterized by a high degree of VEGF-mediated vascular proliferation. In consequence, new targeted anti-angiogenic therapies, such as the monoclonal anti-VEGF-A antibody bevacizumab, have proven effective in attenuating tumor (neo)angiogenesis and were shown to possess therapeutic activity in several phase II trials. However, the role of bevacizumab in the context of multimodal therapy approaches appears to be rather complex. This review will give insights into current concepts, limitations, and controversies regarding the molecular mechanisms and the clinical benefits of bevacizumab treatment in combination with radio(chemo)therapy - particularly in face of the results of recent phase III trials, which failed to demonstrate convincing improvements in overall survival (OS). Impact Journals LLC 2015-11-13 /pmc/articles/PMC4823037/ /pubmed/26575171 http://dx.doi.org/10.18632/oncotarget.6320 Text en Copyright: © 2016 Niyazi et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Review Niyazi, Maximilian Harter, Patrick N. Hattingen, Elke Rottler, Maya von Baumgarten, Louisa Proescholdt, Martin Belka, Claus Lauber, Kirsten Mittelbronn, Michel Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance? |
title | Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance? |
title_full | Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance? |
title_fullStr | Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance? |
title_full_unstemmed | Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance? |
title_short | Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance? |
title_sort | bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823037/ https://www.ncbi.nlm.nih.gov/pubmed/26575171 http://dx.doi.org/10.18632/oncotarget.6320 |
work_keys_str_mv | AT niyazimaximilian bevacizumabandradiotherapyforthetreatmentofglioblastomabrothersinarmsorunholyalliance AT harterpatrickn bevacizumabandradiotherapyforthetreatmentofglioblastomabrothersinarmsorunholyalliance AT hattingenelke bevacizumabandradiotherapyforthetreatmentofglioblastomabrothersinarmsorunholyalliance AT rottlermaya bevacizumabandradiotherapyforthetreatmentofglioblastomabrothersinarmsorunholyalliance AT vonbaumgartenlouisa bevacizumabandradiotherapyforthetreatmentofglioblastomabrothersinarmsorunholyalliance AT proescholdtmartin bevacizumabandradiotherapyforthetreatmentofglioblastomabrothersinarmsorunholyalliance AT belkaclaus bevacizumabandradiotherapyforthetreatmentofglioblastomabrothersinarmsorunholyalliance AT lauberkirsten bevacizumabandradiotherapyforthetreatmentofglioblastomabrothersinarmsorunholyalliance AT mittelbronnmichel bevacizumabandradiotherapyforthetreatmentofglioblastomabrothersinarmsorunholyalliance |